Because SARS-CoV-2 may utilize ISG’s to enhance infectivity, and because it is unclear whether the IFN response restricts SARS-CoV-2 replication, it is unknown if IFN-directed therapies will be beneficial to COVID-19 patients. This evidence concerns the gene IFNA1 and COVID-19.